Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

August Campaign Highlights Total Wellness for Over 8 Million in the U.S. with Psoriasis ALEXANDRIA, VA, UNITED STATES, August 1, 2025 /EINPres ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

Sun Pharmaceutical Industries reported a decline of 20 per cent in net profit at Rs. 2,278.63 crore during the first quarter of the current fiscal year, as compared to Rs. 2,835.62 crore during the ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

Mentoring those newly diagnosed with psoriasis reminds a self-described old-timer of the value of lifestyle, community, and testing one’s limits.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Barclays ...

When a lung nodule is found—whether through routine screening or an incidental scan—it can spark fear, confusion, and ...

“When he first came to us, he was hesitant in speech, struggling to find words and put his thoughts together. By the end, he ...